LKB1 -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80...

7
R 1 tin 1 LKB1 -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA- ER +GFP-KU70/80 or - LKB1 +I-Sce> 200 copies of TRE/I-SceI +Tamoxifen U2OS/TRE/I-SceI- 19 I-SceI TRE site I-SceI TRE site I-SceI Electroporat ion Supplementary Figure S1 LKB1 involvement in DSB repair (a) Sensitivity to IR, bleomycin, camptothecin and etoposide associated with LKB1 depletion. A clonogenic assay was performed using siLKB1 and control siRNA-treated H1299 cells. Mean values (+/- SD) of survivors (determined by the ratio of IR-treated versus untreated cells) for three independent experiments are shown. (b) Cell fractionation experiment. LKB1 proteins detected in the cytoplasm (Cyt), the soluble nuclear fraction (Nuc), and the insoluble nuclear chromatin fraction (Chro.ppt), are shown, with β-actin, EGFR and PARP1 as positive controls. (c) I-SceI DSB assay (ref 19). SiRNA-treated U2OS/TRE/I-SceI- 19 cells were electroporated with pCherry-TBP to express red- fluorescent Cherry-tagged TRE binding protein fused to the estrogen receptor; two plasmids for the expression of GFP- tagged KU70 and KU80; or LKB1 proteins, and the I-SceI expression plasmid. After electroporation, the cells were immediately treated with tamoxifen to induce transport of Cherry-TBP into the nucleus. Foci were examined 6 h after

Transcript of LKB1 -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80...

Page 1: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

EGFR

LKB1β actin

PARP1

Nuc

Chr

Cyt

LKB1

-actin

EGFR

PARP1

Cyto Nuc Chro.

ppt

Cell fractionationb

a

c

6 h+Cherry-tTA-ER+GFP-KU70/80 or -LKB1

+I-SceⅠ

> 200 copies of TRE/I-SceI

+Tamoxifen

U2OS/TRE/I-SceI-19

I-SceI

TRE site

I-SceI

TRE site

I-SceI

Electroporation

Supplementary Figure S1 LKB1 involvement in DSB repair(a) Sensitivity to IR, bleomycin, camptothecin and etoposide associated with LKB1 depletion. A clonogenic assay was performed using siLKB1 and control siRNA-treated H1299 cells. Mean values (+/- SD) of survivors (determined by the ratio of IR-treated versus untreated cells) for three independent experiments are shown.(b) Cell fractionation experiment. LKB1 proteins detected in the cytoplasm (Cyt), the soluble nuclear fraction (Nuc), and the insoluble nuclear chromatin fraction (Chro.ppt), are shown, with β-actin, EGFR and PARP1 as positive controls.(c) I-SceI DSB assay (ref 19). SiRNA-treated U2OS/TRE/I-SceI-19 cells were electroporated with pCherry-TBP to express red-fluorescent Cherry-tagged TRE binding protein fused to the estrogen receptor; two plasmids for the expression of GFP-tagged KU70 and KU80; or LKB1 proteins, and the I-SceI expression plasmid. After electroporation, the cells were immediately treated with tamoxifen to induce transport of Cherry-TBP into the nucleus. Foci were examined 6 h after electroporation.

Page 2: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

Flag-LKB1 +- +- +- +-IR +- +- +- +-

Flag IPWCE

Flag-LKB1

BRM

ATM

Supplementary Figure S2 Interaction between LKB1 and ATM examined by immunoprecipitation (IP) of whole cell extracts (WCE) using anti-FLAG antibody.

Page 3: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

siAM

PK2 #2

AMPK2

-actin

siCon

t

Supplementary Figure S3 Reduced NHEJ activity by AMPK2-depletion using a different set of siRNAs from those used in Figure 3. Results of western blot analysis are also shown.

Fra

ctio

n o

f E

GF

P p

ositi

ve c

ells

Page 4: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

Breaks Radials Breaks Radialssi Control 150 12 (8.0%) 0 (0.0%) 0.093 0.000si LKB1 197 53 (26.9%) 9 (4.6%) 0.645 0.071si AMPK 174 24 (13.3%) 0 (0.0%) 0.188 0.000si LKB1+AMPK 178 50 (28.1%) 8 (4.5%) 0.674 0.067

Metaphases scored

Aberrations per metaphase

Metaphses with aberrations (%)

siRNA Control siRNA LKB1

siRNA AMPK2 siRNA LKB1+AMPK2

a

b

Supplementary Figure S4 Effect of LKB1 and AMPK2 depletion on the number of chromosomal breaks and radials(a) Chromosome breaks and radials in H1299 cells transfected with control, LKB1 and/or AMPK2 siRNA. Slides were Giemsa stained and metaphase spreads were analyzed for the number of chromosomal aberrations.(b) Number of chromosomal aberrations per metaphase spread.

22

Page 5: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

Supplementary Figure S5 Size fractionation of DNA fragments containing breakpoint junctions. Three major recurrent types of repiatred products (Types I–III in ref 23) were observed all in siControl, siLKB1 and siBRM cells. Experimental details are in ref 23.

siControl

siLKB1

siBRM

Page 6: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

Flag IP

Flag-LKB1

Flag-LKB1 kd +-

--

-+

+-

--

-+

WCE

Flag

BRM

Supplementary Figure S6 WT-LKB1 and kd-LKB1 (SL26) interaction with BRM examined by immunoprecipitaion (IP) of whole cell extract (WCE) using anti-FLAG antibody.

Page 7: LKB1  -actin EGFR PARP1 Cyto Nuc Chro.ppt Cell fractionation b a c 6 h +Cherry-tTA-ER +GFP-KU70/80 or -LKB1 +I-Sce Ⅰ > 200 copies of TRE/I-SceI +Tamoxifen.

siAM

PK1

AMPK1

-actin

siCon

t

Supplementary Figure S7 Reduced NHEJ activity in AMPK1-depleted cells. Results of western blot analysis are also shown.

Fra

ctio

n o

f E

GF

P p

ositi

ve c

ells